30
Jan
2012
Posted in I - Series B, Q - 4Q11, R - NORTH EAST, X - Device (Sequencing), XX - MA
PathoGenetix (Woburn, MA) a development-stage sequencing company focused on simultaneous identification and characterization of bacterial strains in a single test, closed a $7.5M Series B financing, bringing the total round to $11.5M. Participants include Ascension Health Ventures, Excel Venture Management, CB Health Ventures and HealthCare Ventures.
26
Jan
2012
26
Jan
2012
26
Jan
2012
26
Jan
2012
26
Jan
2012
Posted in I - Series B, Q - 3Q11, R - WEST, X - Dermatology, X - Inflammation, X - Opthalmology, XX - CA
SARcode (Brisbane, CA) a clinical-stage biopharmaceutical company focused on chronic T-cell mediated inflammation in ophthalmic and dermatologic disease, closed a $44M Series B financing. Participants include Sofinnova Ventures, Rho Ventures, Alta Partners and Clarus Venture Partners.
Thanx for your patience as we catch-up.
26
Jan
2012
Posted in I - Series B, Q - 3Q11, R - MID WEST, X - Device (Diagnostic), X - Oncology, XX - MI
Intervention Insights (Grand Rapids, MI) a commercial-stage personalized medicine company focused on molecularly targeted oncology therapies, closed a $7.2M Series B financing. Participants include Beringea, Chrysalis Ventures, Hopen Life Science Ventures and Michigan Accelerator Fund.
Thanx for your patience as we catch-up.
26
Jan
2012
Posted in I - Series B, Q - 3Q11, R - SOUTH WEST, X - Device (Diagnostic), XX - NM
nanoMR (Albuquerque, NM) a development stage medical device focused on a immunomagnetic capture system for the blood culture market, closed a $13M Series B financing. Participants include Excel Venture Management, Healthcare Ventures, vSpring Capital, Dow Chemical Company and Sun Mountain Capital.
Thanx for your patience as we catch-up.
23
Jan
2012
Posted in I - Series B, Q - 3Q11, R - MID WEST, X - Biomarker, X - Device (Diagnostic), XX - OH
Cleveland Heartlab (Cleveland, OH) a commercial-stage specialty clinical laboratory and disease management company focused on assessing cardiovascular risk, closed a $18.4M Series B financing. Participants include Excel Venture Management and HealthCare Ventures.
Thanx for your patience as we catch-up.
19
Jan
2012
Posted in I - Series B, Q - 3Q11, R - WEST, X - Cardiology, X - Renal, XX - CA
Sorbent Therapeutics (Sunnyvale, CA) a clinical-stage biopharmaceutical company focused on development of adaptable non-absorbed polymeric drugs to for congestive heart failure, chronic kidney disease, end stage renal disease and hypertension, closed a $36M Series B financing. Participants include Novartis Venture Funds, Sofinnova Ventures, ARCH Venture Partners, CMEA Capital and AgeChem.
Thanx for your patience as we [...]
17
Jan
2012
Posted in I - Series B, Q - 3Q11, R - WEST, X - Device (Ophthalmology), XX - CA
Transcend Medical (Menlo Park, CA) a clinical-stage medical device company focused on the treatment of glaucoma, closed a $16 Series B, bringing the total round to $51M. Participants include Investor Growth Capital, Canaan Partners, Finistere Ventures, HLM Venture Partners, Kaiser Permanente Ventures, Latterell Venture Partners, Morgenthaler Ventures, Split Rock Partners and Technology Partners.
Thanx for your [...]
17
Jan
2012
Posted in I - Series B, Q - 3Q11, R - NORTH EAST, X - Oncology, X - Stem Cell, XX - MA
Verastem (Boston, MA) a development stage biopharmaceutical company focused on the treatment of cancer by targeting stem cells, closed a $32M Series B financing. Participants include Advanced Technology Ventures, Astellas Venture Management, Longwood Founders Fund, Bessemer Venture Partners, Cardinal Partners and MPM Capital.
Thanx for your patience as we catch-up.
16
Jan
2012
Posted in I - Series B, Q - 3Q11, R - NORTH EAST, X - Delivery, XX - MA
SpringLeaf Therapeutics (Boston, MA) a preclinical-stage biopharmaceutical company focused on novel delivery mechanisms, closed a $4M Series B financing, bringing the total round to $19M. Participants include Excel Venture Management, SR One, Flybridge Capital Partners and North Bridge Venture Partners.
Thanx for your patience as we catch-up.